Key result
L-glutamine supplementation at 1000 mg/kg significantly improved left ventricular contractility index (48.22 vs 31.25 1/s, p<0.001) and reduced cardiac biomarkers in rats with diabetic cardiomyopathy.
Why the study?
Does L-glutamine prevent the development of experimental diabetic cardiomyopathy in streptozotocin-nicotinamide induced diabetic rats?
Does L-glutamine prevent the development of experimental diabetic cardiomyopathy in streptozotocin-nicotinamide induced diabetic rats?
Absolute Event Rate: 48.22% vs 31.25%
p-value: p=<0.001
L-glutamine supplementation prevents the development of experimental diabetic cardiomyopathy in rats by improving hemodynamics, reducing oxidative stress, and preserving myocardial architecture.
L-glutamine may attenuate experimental diabetic cardiomyopathy in rats; leaves open translation to human therapy.
The objective of the present investigation was to evaluate the effect of L-glutamine on cardiac myopathy in streptozotocin-nicotinamide induced diabetic rats. Diabetes was induced in overnight fasted Sprague Dawely rats by using intraperitonial injection of streptozotocin (55 mg/kg). Nicotinamide (100 mg/kg, i.p.) was administered 20 min before administration of streptozotocin. Experimental rats were divided into Group I: non-diabetic control (distilled water; 10 ml/kg, p.o.), II: diabetic control (distilled water, 10 ml/kg, p.o.), III: L-glutamine (500 mg/kg, p.o.) and IV: L-glutamine (1000 mg/kg, p.o.). All groups were diabetic except group I. The plasma glucose level, body weight, electrocardiographic abnormalities, hemodynamic changes and left ventricular contractile function, biological markers of cardiotoxicity, antioxidant markers were determined after 4 months after STZ with nicotinamide injection. Histopathological changes of heart tissue were carried out by using H and E stain. L-glutamine treatment improved the electrocardiographic, hemodynamic changes; LV contractile function; biological markers; oxidative stress parameters and histological changes in STZ induced diabetic rats. Results from the present investigation demonstrated that L-glutamine has seemed a cardioprotective activity.
No takes yet. Share an insight, caveat, or question.
Badole et al. (2014) studied Diabetic cardiomyopathy (n=24). L-glutamine vs. Diabetic control (distilled water 10 ml/kg p.o.) was evaluated on Left ventricular contractility index (1/s) (p=<0.001). L-glutamine supplementation at 1000 mg/kg significantly improved left ventricular contractility index (48.22 vs 31.25 1/s, p<0.001) and reduced cardiac biomarkers in rats with diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: